Bitcoin groundbreakers share personal stories of how Bitcoin is changing lives for the better. Host Mauricio Di Bartolomeo, co-founder and CSO of Ledn, speaks with leading Bitcoin voices, entrepreneurs, and human rights advocates to hear their unique journey and practical real-world examples of how Bitcoin has made a positive impact in their lives. Brought to you by Ledn, a leading financial services company built for Bitcoin & digital assets. Ledn offers a suite of lending, saving and tradi ...
…
continue reading
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Faron Pharmaceuticals CEO shares positive feedback from US FDA for Phase III BEXMAB trial
MP3•Episode home
Manage episode 428530916 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Faron Pharmaceuticals Limited (AIM:FARN) CEO Dr Juho Jalkanen joined Proactive's Stephen Gunnion with details of the positive feedback from the US Food and Drug Administration (FDA) regarding its Phase III clinical trial for its lead asset, bexmarilimab (BEXMAB). Jalkanen shared that the FDA’s guidance will accelerate trials, potentially bringing new treatments to the market sooner. He explained, “We went with a humble attitude to the FDA, proposing a Phase III trial for relapsed refractory MDS. The big news is that the FDA recommended going directly into a frontline MDS study, opening up a much larger market sooner than anticipated.” This acceleration not only speeds up the process but also targets a larger patient population without significantly increasing trial costs. Jalkanen also highlighted the importance of the Frontrunner program, which promises to bring treatments to patients faster in areas of high unmet need. The feedback from the FDA will significantly impact their commercial forecasts and development plans for BEXMAB. Faron Pharmaceuticals will continue with Phase II trials as planned, aiming to use the results for potential approval in relapsed refractory populations while preparing for Phase III trials in the frontline population next year. Stay updated with more insights from Faron Pharmaceuticals by visiting Proactive's YouTube channel. Don't forget to like, subscribe, and enable notifications for future content. #FaronPharmaceuticals #BEXMAB #FDAApproval #ClinicalTrials #MDSTreatment #BiotechNews #ProactiveInterviews #DrJuhoJalkanen #Pharmaceuticals #MedicalResearch #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
608 episodes
MP3•Episode home
Manage episode 428530916 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Faron Pharmaceuticals Limited (AIM:FARN) CEO Dr Juho Jalkanen joined Proactive's Stephen Gunnion with details of the positive feedback from the US Food and Drug Administration (FDA) regarding its Phase III clinical trial for its lead asset, bexmarilimab (BEXMAB). Jalkanen shared that the FDA’s guidance will accelerate trials, potentially bringing new treatments to the market sooner. He explained, “We went with a humble attitude to the FDA, proposing a Phase III trial for relapsed refractory MDS. The big news is that the FDA recommended going directly into a frontline MDS study, opening up a much larger market sooner than anticipated.” This acceleration not only speeds up the process but also targets a larger patient population without significantly increasing trial costs. Jalkanen also highlighted the importance of the Frontrunner program, which promises to bring treatments to patients faster in areas of high unmet need. The feedback from the FDA will significantly impact their commercial forecasts and development plans for BEXMAB. Faron Pharmaceuticals will continue with Phase II trials as planned, aiming to use the results for potential approval in relapsed refractory populations while preparing for Phase III trials in the frontline population next year. Stay updated with more insights from Faron Pharmaceuticals by visiting Proactive's YouTube channel. Don't forget to like, subscribe, and enable notifications for future content. #FaronPharmaceuticals #BEXMAB #FDAApproval #ClinicalTrials #MDSTreatment #BiotechNews #ProactiveInterviews #DrJuhoJalkanen #Pharmaceuticals #MedicalResearch #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
608 episodes
Όλα τα επεισόδια
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.